Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary nervous-system lymphoma.
Plotkin SR, Batchelor TT. Plotkin SR, et al. Lancet Oncol. 2001 Jun;2(6):354-65. doi: 10.1016/S1470-2045(00)00390-9. Lancet Oncol. 2001. PMID: 11905752 Review.
Primary nervous system lymphoma.
Plotkin SR, Batchelor TT. Plotkin SR, et al. Curr Treat Options Oncol. 2002 Dec;3(6):525-35. doi: 10.1007/s11864-002-0071-7. Curr Treat Options Oncol. 2002. PMID: 12392641 Review.
Peripheral and cranial nerve sheath tumors.
Mrugala MM, Batchelor TT, Plotkin SR. Mrugala MM, et al. Among authors: plotkin sr. Curr Opin Neurol. 2005 Oct;18(5):604-10. doi: 10.1097/01.wco.0000179507.51647.02. Curr Opin Neurol. 2005. PMID: 16155448 Review.
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. Batchelor TT, et al. Cancer Cell. 2007 Jan;11(1):83-95. doi: 10.1016/j.ccr.2006.11.021. Cancer Cell. 2007. PMID: 17222792 Free PMC article. Clinical Trial.
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB. Reardon DA, et al. J Clin Oncol. 2008 Dec 1;26(34):5610-7. doi: 10.1200/JCO.2008.16.7510. Epub 2008 Nov 3. J Clin Oncol. 2008. PMID: 18981465 Clinical Trial.
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK. Batchelor TT, et al. Among authors: plotkin sr. J Clin Oncol. 2010 Jun 10;28(17):2817-23. doi: 10.1200/JCO.2009.26.3988. Epub 2010 May 10. J Clin Oncol. 2010. PMID: 20458050 Free PMC article. Clinical Trial.
195 results